News Release

Tumor cells target metastases as they die

Cancer medication

Peer-Reviewed Publication

Ruhr-University Bochum

Group leaders

image: 

Carlos Plaza Sirvent from Medicine (left) and Johannes Karges from Chemistry worked together on the study.

 

view more 

Credit: © RUB, Marquard

Uncommon: immunogenic cell death

90 percent of all deaths from cancer are due to metastases. This is why Karges and his team are looking for ways to train the immune system to target and eliminate cancer cells. They have found success with a drug that kills the cells in a sophisticated manner. “The gallium complex we developed penetrates the cells and, because of its special properties, causes oxidative stress in a certain cell organelle known as the endoplasmic reticulum,” he explains. “The cells then undergo immunogenic cell death, which only very few drugs can achieve.”

Immune system learns to identify cancer cells

Through this type of cell death, proteins from the endoplasmic reticulum and the cell nucleus are released to the outside and act as a strong warning signal to the immune system: Something is wrong here, these cells are harmful. This teaches the immune system to recognize the cancer cells as hostile and eliminate them throughout the body. This should also destroy metastases.

The two teams led by Johannes Karges and Carlos Plaza-Sirvent have successfully tested the active ingredient on cervical cancer cell lines. The next step is to package it in such a way that it accumulates specifically in cancer cells and is effective only there, and not in all cells of the body. Karges' research group has already developed various methods for this, for example, which active ingredients are activated by an external signal such as ultrasound or light.


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.